The reliable predictive markers to identify which patients with advanced non-small cell lung cancer tumors (NSCLC) will achieve durable clinical benefit (DCB) for chemo-immunotherapy are needed. In ...
Early detection is critical to improving outcomes across many diseases, yet cliniciansmust rapidly interpret heterogeneous signals, reports, and images. Automated analysis helps uncover subtle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results